Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5929
    -0.0005 (-0.09%)
     

  • NZD/EUR

    0.5541
    +0.0000 (+0.00%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    83.03
    -0.33 (-0.40%)
     

  • GOLD

    2,339.60
    -2.50 (-0.11%)
     

  • NASDAQ

    17,553.94
    +82.47 (+0.47%)
     

  • FTSE

    8,041.90
    -2.91 (-0.04%)
     

  • Dow Jones

    38,411.12
    -92.57 (-0.24%)
     

  • DAX

    18,084.99
    -52.66 (-0.29%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • NZD/JPY

    91.8270
    +0.0610 (+0.07%)
     

What Are Amarin’s Earnings Projections for 2018?

Margaret Patrick
Updated
What Are Amarin’s Earnings Projections for 2018?

According to Amarin’s (AMRN) third-quarter earnings conference call, the company secured prescription approval rates of 75% for Vascepa from Managed Care organizations—similar to the approval rates witnessed by generic Lovaza. The company has been witnessing rapid revenue growth for Vascepa, despite a narrow label and low salesforce. Amarin is focused on capacity expansion, which could support more than $1.0 billion worth of Vascepa’s net revenues in 2019.

Continue reading